Đang chuẩn bị liên kết để tải về tài liệu:
Indacaterol on dyspnea in chronic obstructive pulmonary disease: A systematic review and meta-analysis of randomized placebo-controlled trials

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Indacaterol is a novel, once-daily (od), inhaled, long-acting ß2-agonist bronchodilator for maintenance treatment of airflow limitation in patients with COPD. The aim of this study was to evaluate the efficacy of indacaterol on dyspnea, using available randomized placebo-controlled trials. |

TÀI LIỆU LIÊN QUAN

Rapid simultaneous determination of indacaterol maleate and glycopyrronium bromide in inhaler capsules using a validated stability-indicating monolithic LC method

Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: A study level and a patient level network meta-analysis

Báo cáo y học: " Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium"

Báo cáo y học: " Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using modelbased approaches"

Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fxed-dose combination in Japanese and Caucasian healthy subjects

Immediate salbutamol responsiveness does not predict long-term benefits of indacaterol in patients with chronic obstructive pulmonary disease

Indacaterol on dyspnea in chronic obstructive pulmonary disease: A systematic review and meta-analysis of randomized placebo-controlled trials

Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease - a randomized, multicenter, double-blind, placebo-controlled study